STM2457 is the first bioavailable small-molecule inhibitor of METTL3 (a regulator of m6A methyltransferase) that affects the inhibition of catalytic activity and upregulation of METTL3 increasing PD-L1 and reduction of tumor progression in NSCLC (non-small-cell lung cancer) [233]. Here, METTL3 is linked to neoplasm.